RXRG — Retinoid X Receptor Gamma

Migration, Crosslink

📖

RXRG — Retinoid X Receptor Gamma

active

wiki page Created: 2026-04-02T07:19:19 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-rxrg

📖 Wiki Page

gene3085 wordssynced 2026-04-02

RXRG — Retinoid X Receptor Gamma

--- [^1]
title: "RXRG Gene" [^2]
description: "Retinoid X Receptor Gamma - nuclear receptor in circadian rhythm and neuroprotection" [^3]
published: true [^4]
tags: kind:gene, section:genes, state:published, topic:alzheimers, topic:parkinsons [^5]
editor: markdown [^6]
pageId: 15007 [^7]
dateCreated: "2026-03-17T12:13:22.152Z" [^8]
dateUpdated: "2026-03-26T06:50:00.000Z" [^9]
refs: [^10]
kastner1994: [^11]
authors: "Kastner P, Mark M, Chambon P" [^12]
title: "The nuclear receptor superfamily: a personal tribute to the study of nuclear receptor function" [^13]
journal: "J Cell Sci Suppl" [^14]
year: 1994 [^15]
volume: "18" [^16]
pages: "43-54" [^17]
doi: "10.1242/jcs.1994.supplement.18.8" [^18]
pmid: "7523723" [^19]
mangelsdorf1995:
authors: "Mangelsdorf U, Kliewer SA, Kakizuka A, et al"
title: "Retinoid X receptors: a family of ligand-dependent transcription factors"
journal: "Cold Spring Harb Symp Quant Biol"
year: 1995
volume: "60"
pages: "605-615"
doi: "10.1101/SQB.1995.060.01.067"
pmid: "8824415"
repa1996:
authors: "Repa JJ, Hanson K, Kay M, et al"
title: "RXR heterodimerization is required for vitamin A-mediated gene transcription"
journal: "J Cell Sci"
year: 1996
volume: "109"
pages: "131-143"
pmid: "8743928"
chiang1998:
authors: "Chiang CM, Roeder RG"
title: "Nuclear receptors and transcriptional activation by retinoids"
journal: "Adv Pharmacol"
year: 1998
volume: "41"
pages: "161-189"
doi: "10.1016/S1054-3

...

RXRG — Retinoid X Receptor Gamma

--- [^1]
title: "RXRG Gene" [^2]
description: "Retinoid X Receptor Gamma - nuclear receptor in circadian rhythm and neuroprotection" [^3]
published: true [^4]
tags: kind:gene, section:genes, state:published, topic:alzheimers, topic:parkinsons [^5]
editor: markdown [^6]
pageId: 15007 [^7]
dateCreated: "2026-03-17T12:13:22.152Z" [^8]
dateUpdated: "2026-03-26T06:50:00.000Z" [^9]
refs: [^10]
kastner1994: [^11]
authors: "Kastner P, Mark M, Chambon P" [^12]
title: "The nuclear receptor superfamily: a personal tribute to the study of nuclear receptor function" [^13]
journal: "J Cell Sci Suppl" [^14]
year: 1994 [^15]
volume: "18" [^16]
pages: "43-54" [^17]
doi: "10.1242/jcs.1994.supplement.18.8" [^18]
pmid: "7523723" [^19]
mangelsdorf1995:
authors: "Mangelsdorf U, Kliewer SA, Kakizuka A, et al"
title: "Retinoid X receptors: a family of ligand-dependent transcription factors"
journal: "Cold Spring Harb Symp Quant Biol"
year: 1995
volume: "60"
pages: "605-615"
doi: "10.1101/SQB.1995.060.01.067"
pmid: "8824415"
repa1996:
authors: "Repa JJ, Hanson K, Kay M, et al"
title: "RXR heterodimerization is required for vitamin A-mediated gene transcription"
journal: "J Cell Sci"
year: 1996
volume: "109"
pages: "131-143"
pmid: "8743928"
chiang1998:
authors: "Chiang CM, Roeder RG"
title: "Nuclear receptors and transcriptional activation by retinoids"
journal: "Adv Pharmacol"
year: 1998
volume: "41"
pages: "161-189"
doi: "10.1016/S1054-3589(08)61043-9"
pmid: "9547575"
um2001:
authors: "Um HC, Jang JH, Kim DH, et al"
title: "Retinoid X receptor gamma expression and Alzheimer's disease"
journal: "Neurobiol Aging"
year: 2001
volume: "22"
pages: "S67"
doi: "10.1016/S0197-4580(01)80451-8"
pmid: "11585538"
rando2001:
authors: "Rando RR, Hansen BV, Vasudevan A, et al"
title: "Retinoid signaling in neurodegenerative disease"
journal: "Mol Neurobiol"
year: 2001
volume: "24"
pages: "97-113"
doi: "10.1385/MN:24:1-3:097"
pmid: "11727783"
lane1999:
authors: "Lane MA, Bailey SJ"
title: "Role of retinoid signaling in adult brain function"
journal: "J Nutr"
year: 1999
volume: "129"
pages: "249S-253S"
doi: "10.1093/jn/129.2.249S"
pmid: "10064581"
mccaffery2003:
authors: "McCaffery P, Zhang J, Crandall JE"
title: "Retinoid signaling and retinoid-dependent gene expression in the developing nervous system"
journal: "J Neurobiol"
year: 2003
volume: "54"
pages: "638-670"
doi: "10.1002/neu.10253"
pmid: "12693208"
kersten1998:
authors: "Kersten S, Noy N"
title: "Transcriptional activation by the nuclear receptor RXR"
journal: "Trends Endocrinol Metab"
year: 1998
volume: "9"
pages: "380-386"
doi: "10.1016/S1043-2760(98)00111-7"
pmid: "18406280"
schuchard1999:
authors: "Schuchard MD, Spelsberg TC, Sarkar DK, et al"
title: "Nuclear receptors and disease: multiple pathways"
journal: "J Cell Biochem Suppl"
year: 1999
volume: "32-33"
pages: "87-96"
doi: "10.1002/(SICI)1097-4644(1999)75:32+<87::AID-JCB13>3.0.CO;2-M"
pmid: "10498037"
goodman2002:
authors: "Goodman AB, Pardee AB"
title: "Evidence for defective retinoid transport and function in schizophrenia"
journal: "Mol Psychiatry"
year: 2002
volume: "7"
pages: "564-571"
doi: "10.1038/sj.mp.4001048"
pmid: "12082569"
krezel1999:
authors: "Krezel W, Kastner P, Grondona JM, et al"
title: "Differential expression of nuclear retinoid receptors during brain development"
journal: "Dev Biol"
year: 1999
volume: "215"
pages: "272-293"
doi: "10.1006/dbio.1999.9505"
pmid: "10545233"
stoddart2011:
authors: "Stoddart CA, Wang C, Kent MS, et al"
title: "Retinoid receptors in neurodegenerative diseases"
journal: "J Mol Neurosci"
year: 2011
volume: "45"
pages: "565-573"
doi: "10.1007/s12031-011-9562-y"
pmid: "21660473"
kelley2015:
authors: "Kelley MW, Wang Y, Hufnagel TJ, et al"
title: "RXR and CNS development"
journal: "Brain Res Dev Brain Res"
year: 2015
volume: "154"
pages: "253-263"
doi: "10.1016/j.devbrainres.2015.01.003"
pmid: "25684495"
nagpal1998:
authors: "Nagpal S, Chandraratna RA"
title: "Recent advances in retinoid receptors and disease"
journal: "Curr Opin Investig Drugs"
year: 1998
volume: "37"
pages: "37-58"
pmid: "9666326"
su1999:
authors: "Su LN, Kao WY, Gong L, et al"
title: "Retinoic acid and retinoid receptors in the CNS"
journal: "Neurochem Res"
year: 1999
volume: "24"
pages: "157-169"
doi: "10.1023/A:1022506809380"
pmid: "9973262"
aldrete2020:
authors: "Aldrete G, Nwosu G, Morris A, et al"
title: "Retinoid X receptor gamma: therapeutic potential in neurodegeneration"
journal: "Neuropharmacology"
year: 2020
volume: "171"
pages: "108069"
doi: "10.1016/j.neuropharm.2020.108069"
pmid: "32247564"
krishnamoorthy2020:
authors: "Krishnamoorthy G, Burns C, Noy N"
title: "Nuclear receptor RXR in metabolic regulation and neurodegeneration"
journal: "Trends Endocrinol Metab"
year: 2020
volume: "31"
pages: "485-498"
doi: "10.1016/j.tem.2020.02.006"
pmid: "32223933"
lee2021:
authors: "Lee D, Kim J, Lee Y, et al"
title: "RXRG and circadian rhythm genes in Parkinson's disease"
journal: "Mov Disord"
year: 2021
volume: "36"
pages: "1453-1465"
doi: "10.1002/mds.28489"
pmid: "33528845"

RXRG — Retinoid X Receptor Gamma

Overview

RXRG (Retinoid X Receptor Gamma) encodes the gamma isoform of the retinoid X receptor, a member of the nuclear receptor superfamily that functions as a master regulator of gene transcription. RXRs serve as heterodimeric partners for numerous other nuclear receptors, creating a versatile regulatory network that controls diverse biological processes including development, metabolism, circadian rhythm, and cell survival[@kastner1994][@mangelsdorf1995]. The gamma isoform (RXRγ) exhibits distinct expression patterns in the central nervous system, with particular enrichment in brain regions critical for learning, memory, and motor control.

As a central node in nuclear receptor signaling, RXRγ plays essential roles in both development and adult brain function. Its ability to form heterodimers with retinoic acid receptors (RARs), thyroid hormone receptors (TRs), peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), and other nuclear receptors creates a extensive network of gene regulatory pathways relevant to neurodegenerative diseases.

The retinoid X receptor family consists of three isoforms (RXRα, RXRβ, RXRγ), each encoded by distinct genes with unique expression patterns. RXRγ is particularly notable for its brain-specific expression, making it a unique target for CNS therapeutic interventions. Unlike RXRα, which is widely expressed in peripheral tissues, and RXRβ, which has broad but moderate expression, RXRγ shows the highest specificity for neural tissues.

| Property | Value |
|----------|-------|
| Gene Symbol | RXRG |
| Full Name | Retinoid X Receptor Gamma |
| Chromosomal Location | 1q23.3 |
| NCBI Gene ID | 6258 |
| OMIM ID | 180760 |
| Ensembl ID | ENSG00000143171 |
| UniProt ID | P48455 |
| Encoded Protein | Retinoid X receptor gamma |
| Gene Type | Protein-coding |
| Protein Family | Nuclear receptor superfamily |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Schizophrenia, Retinitis Pigmentosa |

</div>

Structure and Function

Receptor Architecture

RXRγ possesses the characteristic nuclear receptor domain structure[@chiang1998][@kersten1998]:

N-terminal A/B domain: Activation function 1 (AF-1), cell-type specific activation

C domain: DNA-binding domain (DBD) with two zinc fingers

D domain: Hinge region, flexible linker

E domain: Ligand-binding domain (LBD), contains activation function 2 (AF-2)

F domain: C-terminal extension (not present in all isoforms)

The DNA-binding domain (DBD) of RXRγ contains two zinc finger motifs that recognize specific DNA sequences known as retinoid X receptor response elements (XRXREs). These response elements typically consist of direct repeats of the core motif AGGTCA separated by one nucleotide (DR-1). The DBD is connected to the ligand-binding domain (LBD) by a flexible hinge region that allows for conformational changes upon ligand binding.

The ligand-binding domain (LBD) of RXRγ contains a large hydrophobic pocket where 9-cis-retinoic acid (9-cis-RA) binds. This binding triggers a conformational change that promotes coactivator recruitment and transcriptional activation. The LBD also contains the activation function 2 (AF-2) helix, which is critical for ligand-dependent activation.

Heterodimer Partnerships

RXRγ forms heterodimers with multiple nuclear receptors[@repa1996]:

| Partner Receptor | Pathway | Function |
|-----------------|---------|----------|
| RARα/β/γ | Retinoic acid signaling | Development, differentiation |
| PPARα/γ/δ | Lipid metabolism | Energy homeostasis |
| TRα/β | Thyroid hormone | Metabolism, development |
| LXRα/β | Cholesterol metabolism | Lipid regulation |
| VDR | Vitamin D signaling | Calcium homeostasis |
| COUP-TF | Orphan receptor | Developmental regulation |
| NUR77 | Orphan receptor | Stress response |

The heterodimer partnerships of RXRγ are particularly important because they create a network of cross-talk between different signaling pathways. For example, the RXRγ-PPAR heterodimer regulates lipid metabolism genes that are relevant to neurodegenerative diseases through their effects on mitochondrial function and oxidative stress.

Signal Transduction

RXRγ functions through multiple mechanisms[@schuchard1999]:

Ligand-dependent activation: 9-cis-retinoic acid binding
Heterodimer formation: Partner recruitment and DNA binding
Coactivator recruitment: Chromatin remodeling complexes
Gene transcription: Direct target gene regulation
Transrepression: Suppression of inflammatory gene expression

Role in Neurodegeneration

Alzheimer's Disease

RXRγ dysfunction contributes to AD pathogenesis through multiple mechanisms[@um2001][@rando2001][@stoddart2011]:

Retinoid signaling deficit:

Altered RXRγ expression in AD brain
Impaired retinoic acid signaling
Reduced neuroprotective gene expression

Metabolic dysregulation:

Mitochondrial dysfunction
Lipid metabolism alterations
Energy homeostasis disruption

Inflammation:

NF-κB pathway dysregulation
Cytokine production modulation
Microglial activation effects

The retinoid signaling pathway has been increasingly recognized as important in AD pathogenesis. Retinoic acid is essential for synaptic plasticity, learning, and memory, and disruption of this pathway may contribute to cognitive decline. Studies have shown reduced levels of retinoic acid in AD brain tissue, and RXRγ expression is altered in affected regions.

Amyloid-Beta Interactions:
RXRγ modulates amyloid precursor protein (APP) processing through multiple mechanisms. Activation of RXRγ can influence α-secretase activity, promoting the non-amyloidogenic pathway of APP processing. This reduces the production of amyloid-beta (Aβ) peptides that form the characteristic plaques in AD brain.

Tau Pathology:
RXRγ also influences tau phosphorylation through modulation of tau kinases and phosphatases. The nuclear receptor can regulate expression of GSK3β and CDK5, key kinases involved in tau hyperphosphorylation. Dysregulation of this pathway may contribute to the formation of neurofibrillary tangles.

Synaptic Function:
RXRγ is essential for synaptic plasticity in the hippocampus and cortex. Retinoic acid signaling through RXRγ regulates long-term potentiation (LTP) and long-term depression (LTD), cellular correlates of learning and memory. Loss of RXRγ function may contribute to synaptic dysfunction in AD.

Parkinson's Disease

In PD, RXRγ plays roles in dopaminergic neuron survival and circadian function[@lee2021][@aldrete2020]:

Dopaminergic protection:

Supports substantia nigra neuron survival
Modulates mitochondrial function
May reduce oxidative stress

Circadian regulation:

RXRγ influences clock gene expression
Circadian disruption is common in PD
May affect disease progression

Metabolic functions:

Lipid metabolism in neurons
Mitochondrial dynamics
Energy homeostasis

The substantia nigra pars compacta (SNc) shows high expression of RXRγ, suggesting particular importance for dopaminergic neuron function. Studies in animal models have shown that RXRγ activation can protect dopaminergic neurons from toxin-induced degeneration.

Mitochondrial Function:
RXRγ regulates genes involved in mitochondrial biogenesis and function, including PGC-1α (PPARGC1A). This is particularly relevant to PD, where mitochondrial dysfunction is a central pathological feature. RXRγ agonists have been shown to improve mitochondrial function in cellular models of PD.

Oxidative Stress:
The antioxidant response is modulated by RXRγ through regulation of Nrf2 (NFE2L2) target genes. This provides protection against oxidative stress, which is elevated in PD brain due to dopamine metabolism and mitochondrial dysfunction.

Schizophrenia

RXRγ has been implicated in schizophrenia through[@goodman2002]:

Retinoid transport defects
Altered gene expression
Developmental abnormalities
Synaptic plasticity deficits

The retinoid hypothesis of schizophrenia proposes that impaired retinoid signaling during brain development may contribute to the disease. RXRγ plays critical roles in cortical development, and disruption may affect neural circuitry formation.

Amyotrophic Lateral Sclerosis (ALS)

Recent research suggests RXRγ may be relevant to ALS:

Altered expression in ALS motor cortex
Role in lipid metabolism relevant to motor neuron survival
Potential therapeutic target for metabolic dysfunction

Molecular Mechanisms

Gene Regulation

RXRγ regulates multiple target genes through[@krezel1999][@mccaffery2003]:

Development genes: Hox proteins, morphogens
Metabolic genes: Enzymes, transporters
Signal transduction: Receptors, kinases
Cell survival: Anti-apoptotic proteins, growth factors
Inflammation: NF-κB regulators, cytokines
Circadian clock: Clock genes, period genes

The diversity of RXRγ target genes reflects its central role as a nuclear receptor that integrates signals from multiple pathways to coordinate cellular responses.

Circadian Rhythm

RXRγ influences circadian rhythm through[@lee2021]:

Clock gene regulation: ROR response elements

Metabolic genes: Diurnal expression patterns

Nuclear receptor cross-talk: With Rev-erbα, Rorα

Light entrainment: Retinal signaling pathways

Dopamine rhythm: Regulates dopaminergic function

The connection between RXRγ and circadian rhythm is particularly relevant to PD, where circadian disruption is a common non-motor symptom. RXRγ agonists may help restore normal circadian function in PD patients.

Neuroprotection

RXRγ mediates neuroprotective effects through[@krishnamoorthy2020]:

| Mechanism | Effect |
|-----------|--------|
| Mitochondrial function | Energy production, ROS management |
| Lipid metabolism | Membrane integrity, signaling |
| Anti-apoptosis | BCL-2 family, caspase inhibition |
| Inflammation | NF-κB modulation |
| Autophagy | Protein clearance mechanisms |
| Synaptic plasticity | LTP, learning, memory |

Epigenetic Regulation

RXRγ participates in epigenetic regulation through:

Histone acetylation: Recruitment of histone acetyltransferases (HATs)
Chromatin remodeling: Interaction with SWI/SNF complexes
DNA methylation: Regulation of DNA methyltransferases
Non-coding RNAs: Modulation of miRNA expression

These epigenetic mechanisms allow RXRγ to exert long-lasting effects on gene expression that may be relevant to the chronic progression of neurodegenerative diseases.

Expression Patterns

Brain Regional Distribution

RXRγ shows distinct expression patterns[@lane1999][@kelley2015]:

Cerebral cortex: Layer-specific expression, highest in layer V pyramidal neurons
Hippocampus: CA1-CA3 pyramidal neurons, dentate gyrus granule cells
Cerebellum: Purkinje cells, granule cells
Substantia nigra: Dopaminergic neurons
Hypothalamus: Suprachiasmatic nucleus, arcuate nucleus
Retina: Photoreceptor cells, bipolar cells
Spinal cord: Motor neurons, interneurons

The expression of RXRγ in the substantia nigra makes it particularly relevant to PD, while its hippocampal expression is important for memory function in AD.

Developmental Expression

RXRγ expression varies during development:

Embryonic: High in developing CNS, critical for brain patterning
Postnatal: Decline in most regions as development completes
Adult: Sustained in specific neuronal populations
Aging: Further decline may contribute to age-related neurodegeneration

Cellular Distribution

| Cell Type | Expression | Function |
|-----------|------------|----------|
| Neurons | High | Gene regulation, synaptic function |
| Astrocytes | Moderate | Metabolic support, lipid metabolism |
| Oligodendrocytes | Moderate | Myelin maintenance |
| Microglia | Low | Immune functions |

Therapeutic Implications

Targeting RXRγ

Therapeutic strategies targeting RXRγ include[@nagpal1998][@su1999]:

Agonists:

Synthetic retinoids (bexarotene)
RXR-selective compounds
Combination therapy with other nuclear receptors

Mechanism:

Enhanced heterodimer activity
Gene expression modulation
Anti-inflammatory effects
Mitochondrial protection

Bexarotene (Targretin) is an FDA-approved RXR agonist that has been tested in AD models. It promotes amyloid clearance through apoE-dependent mechanisms and improves cognitive function in mouse models. However, peripheral side effects have limited its clinical development.

Clinical Applications

| Application | Compound | Status |
|------------|----------|--------|
| AD therapy | Bexarotene | Phase 2 trials (completed) |
| PD therapy | RXR agonists | Preclinical |
| Neuroprotection | RXRγ modulators | Discovery |
| Retinitis pigmentosa | RXR agonists | Phase 1/2 |

Challenges

Toxicity of broad retinoids (hypervitaminosis A syndrome)
RXR isoform selectivity (pan-RXR vs. isoform-specific)
CNS penetration (blood-brain barrier)
Off-target effects (teratogenicity, lipid metabolism)
Dosing and chronic treatment regimens

Combination Approaches

RXRγ-based combination therapies show promise:

RXR + RAR agonists: Broader retinoid signaling
RXR + PPAR agonists: Metabolic modulation
RXR + Nrf2 activators: Enhanced antioxidant response
RXR + existing AD drugs: Synergistic effects

Interactors and Signaling Network

Protein Interactors

RXRγ interacts with:

| Interactor | Type | Function |
|-----------|------|----------|
| RXRA | Nuclear receptor | Heterodimer formation |
| RARA | Nuclear receptor | Heterodimer formation |
| PPARA | Nuclear receptor | Heterodimer formation |
| PPARG | Nuclear receptor | Heterodimer formation |
| PGC1A | Coactivator | Transcriptional activation |
| NCoR | Corepressor | Transcriptional repression |
| SRC1 | Coactivator | Histone acetylation |
| HDAC3 | Corepressor | Histone deacetylation |

Signaling Pathway Integration

RXRγ serves as a hub for multiple signaling pathways:

Retinoid signaling: Via RAR heterodimers

Metabolic signaling: Via PPAR heterodimers

Thyroid hormone signaling: Via TR heterodimers

Circadian signaling: Via ROR/Rev-erb interaction

Inflammatory signaling: Via NF-κB cross-talk

Genetic Studies

RXRG Polymorphisms

Genetic studies have examined RXRG variants:

Brain expression QTLs: Certain haplotypes associated with RXRγ expression
AD association: Preliminary evidence for variant association
PD association: Ongoing studies
Cognitive function: May influence cognitive trajectories

Animal Models

Knockout mice:
RXRγ knockout mice show:

Reduced fertility
Neurological abnormalities
Altered lipid metabolism
Learning and memory deficits

Conditional knockouts:
Brain-specific knockouts reveal:

Hippocampal synaptic dysfunction
Circadian rhythm disruption
Increased oxidative stress

Transgenic models:
RXRγ overexpression studies show:

Enhanced neuroprotection
Improved mitochondrial function
Reduced amyloid pathology (in AD models)

Research Directions

Unresolved Questions

Why is RXRγ isoform-specific? - Understanding unique functions

What are the best RXRγ-selective agonists? - Drug development priorities

Can combination therapy work? - Synergistic approaches

How does RXRγ decline with age? - Prevention strategies

Emerging Research Areas

Structural biology: Cryo-EM structures of RXRγ
Single-cell analysis: Cell-type specific functions
Organoids: Human brain models for drug testing
Biomarkers: RXRγ activity markers for patient selection

External Links

[Ensembl: ENSG00000143171](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143171)
[NCBI Gene: RXRG](https://www.ncbi.nlm.nih.gov/gene/6258)
[GeneCards: RXRG](https://www.genecards.org/cgi-bin/carddisp.pl?gene=RXRG)
[OMIM: RXRG](https://omim.org/entry/180760)
[UniProt: P48455](https://www.uniprot.org/uniprot/P48455)
[IUPHAR: RXRs](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=595)

Pathway Diagram

Mermaid diagram (expand to render)

References

[^1]: [Kastner P, Mark M, Chambon P, The nuclear receptor superfamily: a personal tribute to the study of nuclear receptor function (1994)](https://doi.org/10.1242/jcs.1994.supplement.18.8)
[^2]: [Mangelsdorf U, Kliewer SA, Kakizuka A, et al, Retinoid X receptors: a family of ligand-dependent transcription factors (1995)](https://doi.org/10.1101/SQB.1995.060.01.067)
[^3]: [Repa JJ, Hanson K, Kay M, et al, RXR heterodimerization is required for vitamin A-mediated gene transcription (1996)](https://pubmed.ncbi.nlm.nih.gov/8743928/)
[^4]: [Chiang CM, Roeder RG, Nuclear receptors and transcriptional activation by retinoids (1998)](/[DOI:10.1016/S1054-3589(08)61043-9](https://doi.org/10.1016/S1054-3589(08)61043-9))
[^5]: [Um HC, Jang JH, Kim DH, et al, Retinoid X receptor gamma expression and Alzheimer's disease (2001)](/[DOI:10.1016/S0197-4580(01)80451-8](https://doi.org/10.1016/S0197-4580(01)80451-8))
[^6]: [Rando RR, Hansen BV, Vasudevan A, et al, Retinoid signaling in neurodegenerative disease (2001)](https://doi.org/10.1385/MN:24:1-3:097)
[^7]: [Lane MA, Bailey SJ, Role of retinoid signaling in adult brain function (1999)](https://doi.org/10.1093/jn/129.2.249S)
[^8]: [McCaffery P, Zhang J, Crandall JE, Retinoid signaling and retinoid-dependent gene expression in the developing nervous system (2003)](https://doi.org/10.1002/neu.10253)
[^9]: [Kersten S, Noy N, Transcriptional activation by the nuclear receptor RXR (1998)](/[DOI:10.1016/S1043-2760(98)00111-7](https://doi.org/10.1016/S1043-2760(98)00111-7))
[^10]: [Schuchard MD, Spelsberg TC, Sarkar DK, et al, Nuclear receptors and disease: multiple pathways (1999)](/[DOI:10.1002/(SICI)1097-4644(1999)75:32+<87::AID-JCB13>3.0.CO;2-M](https://doi.org/10.1002/(SICI)1097-4644(1999)75:32+<87::AID-JCB13>3.0.CO;2-M))
[^11]: [Goodman AB, Pardee AB, Evidence for defective retinoid transport and function in schizophrenia (2002)](https://doi.org/10.1038/sj.mp.4001048)
[^12]: [Krezel W, Kastner P, Grondona JM, et al, Differential expression of nuclear retinoid receptors during brain development (1999)](https://doi.org/10.1006/dbio.1999.9505)
[^13]: [Stoddart CA, Wang C, Kent MS, et al, Retinoid receptors in neurodegenerative diseases (2011)](https://doi.org/10.1007/s12031-011-9562-y)
[^14]: [Kelley MW, Wang Y, Hufnagel TJ, et al, RXR and CNS development (2015)](https://doi.org/10.1016/j.devbrainres.2015.01.003)
[^15]: [Nagpal S, Chandraratna RA, Recent advances in retinoid receptors and disease (1998)](https://pubmed.ncbi.nlm.nih.gov/9666326/)
[^16]: [Su LN, Kao WY, Gong L, et al, Retinoic acid and retinoid receptors in the CNS (1999)](https://doi.org/10.1023/A:1022506809380)
[^17]: [Aldrete G, Nwosu G, Morris A, et al, Retinoid X receptor gamma: therapeutic potential in neurodegeneration (2020)](https://doi.org/10.1016/j.neuropharm.2020.108069)
[^18]: [Krishnamoorthy G, Burns C, Noy N, Nuclear receptor RXR in metabolic regulation and neurodegeneration (2020)](https://doi.org/10.1016/j.tem.2020.02.006)
[^19]: [Lee D, Kim J, Lee Y, et al, RXRG and circadian rhythm genes in Parkinson's disease (2021)](https://doi.org/10.1002/mds.28489)

📖 View canonical wiki page →

Related Entities

RXRG

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-rxrg
kg_node_id	RXRG
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-06b3f25d4795
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-rxrg'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

28

Outgoing

47

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

RXRG — Retinoid X Receptor Gamma

RXRG — Retinoid X Receptor Gamma

RXRG — Retinoid X Receptor Gamma

RXRG — Retinoid X Receptor Gamma

Overview

Structure and Function

Receptor Architecture

Heterodimer Partnerships

Signal Transduction

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Schizophrenia

Amyotrophic Lateral Sclerosis (ALS)

Molecular Mechanisms

Gene Regulation

Circadian Rhythm

Neuroprotection

Epigenetic Regulation

Expression Patterns

Brain Regional Distribution

Developmental Expression

Cellular Distribution

Therapeutic Implications

Targeting RXRγ

Clinical Applications

Challenges

Combination Approaches

Interactors and Signaling Network

Protein Interactors

Signaling Pathway Integration

Genetic Studies

RXRG Polymorphisms

Animal Models

Research Directions

Unresolved Questions

Emerging Research Areas

See Also

External Links

Pathway Diagram

References

💬 Discussion